ReviewWorld journal of clinical pediatrics2026
Interface between inborn errors of immunity and rheumatological disorders in children: A pediatrician's conundrum.
Review in World journal of clinical pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatological disorders encompass a broad and complex spectrum of conditions, often driven by dysregulated immune responses and autoantibody formation. Increasing evidence highlights the significant overlap between rheumatological diseases and inborn errors of immunity (IEIs). The 2024 update of the International Union of Immunological Societies phenotypic classification describes 559 IEI, including 67 novel monogenic defects and 2 new phenocopies. This review examines the clinical spectrum of rheumatological manifestations associated with IEIs, encompassing arthritis, cytopenias, vasculitis, macrophage activation syndrome, systemic lupus erythematosus, inflammatory bowel disease phenotypes, polyautoimmunity, and autoimmune lung disease. Several soft clinical "red flags" can alert physicians to an IEI in a child with rheumatological disease, including very early age of onset, atypical or severe disease course, recurrent or unusual infections, lymphoproliferation, multi-organ autoimmunity, and poor or refractory response to standard therapies. Understanding the mechanisms of immune dysregulation in IEIs provides critical insight into their clinical expression. Defects in central and peripheral tolerance checkpoints, impaired T- and B-cell regulation, abnormal cytokine signaling, and skewed interferon responses contribute to the loss of self-tolerance and autoimmunity. Pediatric rheumatologists and pediatricians should remain highly vigilant for IEI when evaluating children who present with atypical, severe, or treatment-resistant rheumatologic conditions. While these disorders may mimic polygenic autoimmunity, their aggressive nature, multi-system involvement, and association with infections often distinguish them. Early genetic diagnosis not only clarifies prognosis but also enables precision-based therapies, significantly improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.